31

Jul2015

The PMPRB has released its July 2015 NEWSletter

Topics covered in the NEWSletter include: Soliris Pre-Hearing Conference New Staff Member – Legal Services Update: Compendium of Policies, Guidelines and Procedures Part C – Guidelines and Procedures Schedule 9 – CPI-Adjustment Methodology Schedule 2 – Comparable Dosage Forms 2016 HDAP Meeting Schedule & Filing Requirements: February 29 May 2 September 12 November 28 PMPRB Transition to Canada.ca Update: Germany Recognized Price Source Summary ... Read More

27

Jul2015

Ontario Public Drug Programs Division

Proposal to Amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act The Ministry of Health and Long-Term Care is proposing to reform the Ontario Drug Benefit (ODB) program in order to make it more efficient, effective and sustainable. Proposed amendments ... Read More

20

Jul2015

Exceptional Response to PDCI/H3 Private Payer PLA Survey

PDCI & H3 Survey on Private Payer Product Listing Agreements Now “Closed” for Responses As noted in the June 24th TargetPharma, PDCI Market Access (www.pdci.ca) and H3 Consulting (www.hthree.ca) are collaborating on a survey to gauge the interest, expectations, and experience associated with private payer product listing agreements (PLAs). Surveys ... Read More

24

Jun2015

Private Payer PLA Survey

PDCI & H3 Survey on Private Payer Product Listing Agreements Interest, Experience & Expectations Private payers – the community of insurers, Pharmacy Benefit Managers (PBMs) and employers in Canada – are starting to build internal competencies aimed at negotiating product listing agreements (PLAs) with pharmaceutical companies. For the past several years, private ... Read More

23

Jun2015

Australia’s Pharmaceutical Benefits Advisory Committee Recommends Substitution of Biosimilars

Currently in Canada, switching and substitutability between originator biologics and biosimilars has not been established, however that is not the case internationally. Earlier this year the Dutch Medicines Evaluation Board (MEB) supported switching patients from an innovator biologic to a biosimilar, so long as health professionals are involved and the ... Read More

12

Jun2015

QUÉBEC – INESSS Submission Deadlines: 2015-2016

The Minister of Health and Social Services has authorized three updates to the List of Medications covered by the basic prescription drug insurance plan and the List of Medications – Institutions in 2016: February 1, June 1 and October 3, 2016. Updates to the lists of medications for multisource generic ... Read More

25

Mar2015

PDCI Canadian Drug Claims Database FREE TRIAL now available!

PDCI is now offering a FREE TRIAL of its Canadian Drug Claims Database. For those who are interested in the database and would like to learn more, this free trial gives registrants the opportunity to explore the database and test out its functionality at no cost! For more information and to register, please ... Read More

02

Mar2015

‘Successful CDR, pCODR & INESSS Submissions’ Workshop CANCELLED

PDCI's pre-conference workshop at the upcoming Canadian Institute: Pharma Symposium Canada 2015 has been cancelled. For those who may still be interested in the workshop, PDCI is more than happy to provide the workshop in the form of a Webinar or in-house training. Please contact Andrew Brooke for more information on ... Read More